Shawn Nock, mrniceguy@uswest.net ------=_NextPart_000_0005_01BF553D.F160C440-- From gmxa@gmxatf.net Fri Jan 7 06:19:24 2000 Received: from mail.ned-unet.ocn.ne.jp (mail.ned-unet.ocn.ne.jp [210.160.128.98]) by guadalquivir.fnet.fr with ESMTP (8.8.8/97.02.12/Guadalquivir); id GAA26192; Fri, 7 Jan 2000 06:19:19 +0100 (MET) Received-Date: Fri, 7 Jan 2000 06:19:19 +0100 (MET) From: gmxa@gmxatf.net Received: from oemcomputer by mail.ned-unet.ocn.ne.jp (AlliedTelesis SMTPRS 1.1 pl 1 ++DD8482D8CE21D2218A5C0B7AD55FC668) with SMTP id ; Fri, 7 Jan 2000 14:19:42 +0900 Date: Fri, 7 Jan 2000 14:19:42 +0900 Message-ID: To: lisahams@123india.com Subject: ATTENTION SHAREHOLDERS & INVESTORS! SHAREHOLDER & INVESTOR ALERT! ImmuNis Corp a small Biotech Stock with Big Potential. The Stock Savvy Investor Forum recommends that you evaluate the investment potential of ImmuNis Corp shares. ImmuNis Corp (OTCBB: IMMCE), owns a major interest in a new class of oral diabetes medication. The drug is referred to as DIAB II and has been approved for sale in China and is the final stages of the application and registration process in Brazil. ImmuNis purchased its 25% interest in the commercial rights to DIAB II in 1998 for territories outside of Oriental Asia. DIAB II is an insulin-receptor sensitizer, a new class of drugs for controlling the chronically high blood sugar levels that typify adult-onset or Type II diabetes. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that controls blood sugar levels. Adult-Onset Diabetes is an illness affecting more than 15 million Americans and more than 150 million people around the world. The drug -- DIAB II -- provides excellent control of diabetes symptoms without the side-effects of many competing drugs that are already on the market. ImmuNis Corp. has about 8.5 million shares outstanding and at $1.50 per share price has a market capitalization of under $15 million in a market segment where the majority of companies trade with $100 million valuations in anticipation of a new discovery or development. DIAB II confirmed the DIAB II is safe and effective. The market for Type II diabetes drugs is over $15 billion annually. We believe that one should carefully evaluate the potential for a much higher stock market valuation of ImmuNis's share price. Many analysts are pointing out that companies like ImmuNis with the potential of success could produce gains comparable to what has been realized in the Dot Com sector. DIAB II was developed by Biotech Holdings Ltd., a Canadian-based pharmaceutical company, which controls the worldwide manufacturing and marketing rights to the drug. In a June 9, 1999 announcement Biotech also pointed out that there is a sizable and very lucrative market potential for DIAB II in Brazil and throughout Latin America -- that for each one percent of the diabetic population in Brazil, Argentina and Venezuela using DIAB II (a total of 100,000 one-year prescriptions) -- DIAB II sales revenues generated would be over $20,000,000 annually. ImmuNis has a 25% interest in all net revenues from the sale of DIAB II in these Latin American Territories as well as in North America and Europe. In addition to its focus on Latin American markets where license agreements have been completed in Brazil with Biobras, which is the fourth largest insulin manufacturer in the world with 75% of the diabetes medication market in Brazil. Agreements have also been completed in Argentina, Venezuela, Peru and Chile. An agreement with a major (more than $10 billion in sales) pharmaceutical company was announced in September of 1999, that foresees potential licensing of DIAB II, for the U.S. market. Biotech expects to be working closely with this prospective licensing partner to review data and arrange for testing of DIAB II. The goal is to reach a licensing agreement that would provide for testing of DIAB II and filing of an application with the U.S. FDA, with the possibility that other markets could also be included in a final agreement. Biotech Holdings completed the first phase of its drug production facility Canadian Health Pr otection Branch, that certifies that Biotech has met GMP (Good Manufacturi in Richmond, B.C. This notice of approval brings DIAB II to the final stages of entering the market in Brazil and throughout Latin American. Registration dossiers for the sale of DIAB II are now planned for submission in Chile, Argentina, Venezuela and Peru. Registration filings are also expected in the Middle East, Southern Europe and Africa. The DIAB II Brazilian clinical trials provided supplementary information for the regulatory application for approval of DIAB II, in Brazil as a prescription treatment for Type II or Adult-Onset Diabetes. The trial was carried out by one of the largest independent contract research laboratories in Brazil, working with Brazilian doctors specializing in diabetes. The trials showed that during DIAB II treatment that no adverse clinical events were reported. Plasma insulin, HDL/LDL ratio and triglycerides were controlled equally well with DIAB II treatment as on the patients' accustomed medication. The critical Hb A1c measurement showed reduced levels during the course of the study, to an average of 5.85%, (well within normal ranges) indicating excellent diabetic control The shares of ImmuNis represent a opportunity for very substantial gains. However, the shares must be regarded as speculative. Even though the indications are that the drug will continue to prove to be safe and effective, obtaining final approval for sale and distribution in Western Countries may take time or may not occur at all. We always recommend that one investigate and evaluate the potential and risks of any investment. Visit the company's website at http://204.4.8.16 or send us an E-mail at cci@bangkok.com or call (805) 446-1189 for more info today. Nothing in this e-mail shou ld be construed as a solicitation. Please consult an investment professional. This is an alert and is for INFORMATIONAL purposes only. The Stock Savvy Investor takes pride in our careful efforts to reach people who are truly interested in what we have to offer. You have received this message via a news service subscription or an affiliation of such. If in error, please delete or email: (Remove2@whatever) please. : : : : : : : : : : : : : : : : : : : : : : : : : : : From <@Cologne.DE:karsten@excalibur.cologne.de> Fri Jan 7 21:06:48 2000 Received: from fileserv2.Cologne.DE (fileserv2.cologne.de [193.29.188.3]) by guadalquivir.fnet.fr with SMTP (8.8.8/97.02.12/Guadalquivir); id VAA02260; Fri, 7 Jan 2000 21:06:47 +0100 (MET) Received-Date: Fri, 7 Jan 2000 21:06:47 +0100 (MET) Received: from localhost (1039 bytes) by fileserv2.Cologne.DE via rmail with P:stdio/R:bind/T:smtp (sender: ) (ident using unix) id for ; Fri, 7 Jan 2000 21:06:46 +0100 (CET) (Smail-3.2.0.101 1997-Dec-17 #5 built 1998-Jan-19) Received: (from karsten@localhost) by excalibur.cologne.de (8.9.3/8.8.7) id RAA05602; Fri, 7 Jan 2000 17:59:55 +0100 Message-ID: <20000107175955.A5598@excalibur.cologne.de> Date: Fri, 7 Jan 2000 17:59:55 +0100 From: Karsten Merker To: linux-mips@fnet.fr Subject: New .mipsel.rpm packages available Mail-Followup-To: linux-mips@fnet.fr Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii X-Mailer: Mutt 0.91i X-No-Archive: yes Hallo everyone, I have uploaded new .mipsel.rpms to bolug.uni-bonn.de, most of them built from the RedHat-6.1-SRPMs but also some contrib packages including a small word processor (Ted). ftp://bolug.uni-bonn.de/mips/ Greetings, Karsten -- #include Nach Paragraph 28 Abs. 3 Bundesdatenschutzgesetz widerspreche ich der Nutzung oder Uebermittlung meiner Daten fuer Werbezwecke oder fuer die Markt- oder Meinungsforschung.